Fastbase Solutions goal is to develop its microscopy platform, QF-Pro®, into an easy-to-use marketable healthcare product, that contributes to enhance immune-oncology treatments of cancer patients. Fastbase was founded by leading scientists from Cancer Research UK. After promising trial results,they now require funding to launch QF-Pro® commercially.
We founded Fastbase with the goal of improving the lives of cancer patients. As cancer deaths exceed 10m people per year in 2020, we are developing a solution to target one of the root causes of cancer deaths: delivering proper diagnostics.
Therefore, we have developed QF-Pro®, a molecular imaging technology that can map & quantify protein interactions & post-translational modifications in biopsies. These are important biological events. According to our research, their quantification by QF-Pro® can stratify patients for correct treatments, predict patient responses and survival. Our research indicates that no other product is currently offering a higher molecular resolution.
●Cooperating with renowned laboratories worldwide
●Demonstrated value in predicting patient response to immune-therapies & can predict patient survival in lung & skin cancer (published in Cancer Research)
●QF-Pro® technology is protected by patents & licenses in the main markets
●Won two international awards:the EU seal of excellence & MATWIN award in 2020.
We require funding to begin our next phase: fully productising QF-Pro® & translating it to research & clinical laboratories worldwide. We believe it could improve patient outcomes of immune-oncology therapies. Our own research suggests we could expand into other diseases. The Immuno-oncology market is expected to grow at 16.5% CAGR to $37bn by 2028.